×
ADVERTISEMENT

cobimetinib

FDA Grants New Indication for Tecentriq Plus Cotellic and Zelboraf for Advanced Melanoma

The new combination increased PFS to a median of 15.1 months compared with placebo plus cobimetinib and vemurafenib ...

AUGUST 4, 2020

New Data Confirm Cobimetinib-Vemurafenib Combo as a New Standard

Long-term data from the pivotal coBRIM trial, which explored combination cobimetinib (Cotellic, Genentech) and ...

SEPTEMBER 14, 2016

Load more